PeerView Oncology & Hematology CME/CNE/CPE Video Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share





Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care


Go online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ultimately improve care for their patients with MM. Upon completion of this accredited CE activity, participants should be better able to: Summarize current evidence about the use of novel antibody platforms targeting CD38 and BCMA in relapsed/refractory multiple myeloma (RRMM), including in heavily pretreated disease, Integrate antibody-based therapies into team treatment plans for the management of patients with RRMM, Develop team-based strategies addressing practical aspects of antibody therapy in RRMM, including issues related to dosing/scheduling, unique safety considerations such as neutropenia, infection, and ocular toxicity, and patient and staff education on drug safety/delivery.


share







 2021-10-14  1h4m